Global CAR T-Cell Therapy Market Size, Segmentation, Trends and Growth Analysis Forecast by 2030

CAR T-cell therapy Market Overview and Analysis:

The global CAR T-cell therapy market size was evaluated at USD 3.82 billion in 2022, registering a CAGR of 29.8% from 2023 to 2030.

Get Complete Analysis Of The Report - Download Free Sample PDF

Chimeric antigen receptor (CAR) T-cell therapy is a new type of cancer treatment, in which healthcare professionals change to T-cells in the lab and then infuse them into the body of a cancer patient, so they can find and destroy cancer cells. CAR T-cell therapy is a method of training the immune system to recognize cancerous cells. It is called gene or cell therapy. CAR T-cell therapy is used to enhance the immune response against cancerous cells. 

Drivers : 

Increased prevalence of cancer 

The CAR-T cell therapy market is expanding due to increasing patient assistance programs (PAPs), growing government measures to raise cancer awareness, rising cancer prevalence globally, and robust R&D investments from major companies. As the demand for cell-based therapy grows, manufacturers have begun to invest in its development. An increase in cancer incidence is estimated to fuel the expansion of the global CAR T-Cell treatment market during the projected period. Cancer is the leading cause of death in the world.

Most cancer cases are caused by lifestyle factors such as drinking alcohol and smoking and some dietary components such as nitrites and polyaromatic hydrocarbons. Another primary driver of the requirement for CAR T-Cell therapy products is the robust product pipeline. For instance, AUTO1, an innovative product from Autolus Therapeutics plc, is undergoing a phase I trial to treat adult acute lymphoblastic leukemia. An investigational cell therapy, AUTO1 containing a CD19 CAR T-Cell, is designed to overcome clinical safety and activity limitations associated with existing CD19 CAR T-Cell therapies.

CAR T-cell therapy Market Rising awareness and increase in approval of novel medications

The development of new technology and increasing awareness regarding CAR-T cells generates "armored CARs" that co-express pro-inflammatory cytokine like IL-12 or IL-15. It increases CAR T-Cell proliferation and persistence at the beginning of tumor-mediated immunosuppression.

Restraints :

Side effects of CAR-T cell therapy.

Like all cancer treatments, CAR T-cell therapies have serious side effects, such as a mass death of antibody-producing B cells and infections. Cytokine release syndrome (CRS) is one of the most common and severe side effects. T cells release chemical messengers (cytokins) which stimulate and direct immune responses as part of immune-related duties.

In the case of CRS, the infused T cells flood the bloodstream with cytokines, resulting in serious side effects such as highly elevated fevers and sudden drops in blood pressure. Severe CRS can be fatal in some cases. Another primary concern with CAR T-Cell therapies is neurologic side effects such as extreme confusion, seizure-like activity, and impaired speech. The exact cause of these neurologic side effects (immune effector cell-associated neurotoxicity syndrome, or ICANS) is unknown.

COVID-19 Impact on CAR T-cell therapy Market

The COVID-19 pandemic had a negative impact on the CAR T-cell therapy market because priority is given to COVID-19 patients for treatment. Discovery and development of CAR T-cell therapy medicine slowed down during the pandemic but did not stop. The significant reduction in clinical trials due to strict government guidelines against COVID-19 resists the growth of the CAR T-cell therapy market. The decline in people transit, the closing of borders, and the confinement of the population impacted the supply chains of these life-saving medical products in the CAR T-cell therapy market. 

Segmentation: 

The CAR T-Cell Therapy Market is segmented

By Types :

• Abecma
• Breyanzi
• Kymriah
• Tecartus
• Yescarta
• Others

By Applications  :

• Leukemia
• Lymphoma
• Multiple Myeloma
• Autoimmune Disorders
• Other

End Users :

• Hospitals
• Cancer Care Treatment Centers

Geography

• North America
• Europe
• Asia-Pacific
• Middle East
• Africa
• South America

The report offers the value (in USD million) for the above segments.

For Detailed Market Segmentation - Download Free Sample PDF

CAR T-Cell Therapy Market Segmental Analysis

Multiple Myeloma Segment is Expected to Witness Significant Growth Over the Forecast Period 

Multiple myeloma develops in a white blood cell known as a plasma cell. Healthy plasma cells produce antibodies that can identify and destroy microorganisms, aiding in the battle against infections. In multiple myeloma, cancerous plasma cells accumulate in the bone marrow and eliminate good blood cells. It causes the production of abnormal proteins, called paraproteins, which can build up in the body and damage organs and tissues. Anemia, frequent infections, bone discomfort, and kidney issues are the associated issues with multiple myeloma.

Treatment options include stem cell transplantation, radiation treatment, chemotherapy, and targeted therapy. Rise in prevalence of multiple myeloma is attributed to increase in demand for medications, immunotherapy, radiation therapy, stem cell transplantation procedure, and plasmapheresis. According to the International Agency for Research on Cancer, around 1,76,404 cases of multiple myeloma were reported over the globe in 2020. In addition, in 2023, the American Cancer Society estimated that around 35,730 new cases of multiple myeloma will be diagnosed in the U.S. Thus, rise in prevalence of multiple myeloma over the globe is expected to boost the segment’s growth. 

North America is Expected to Hold a Significant Share in the Market and Expected to do Same Over the Forecast Period

North America is expected to witness growth in the studied market owing to the increasing burden of chronic disorders such as cancer and autoimmune disorders, growth in research and development activities, and strong and established market players. The growing number of investments contributes to market growth. For instance, in June 2021, Blackstone reported that funds managed by Blackstone Life Sciences had committed USD 250 million towards the launch of a new autologous and allogeneic universal chimeric antigen receptor (CAR) T-cell therapy company, along with Intellia Therapeutics, Inc. and Cellex Cell Professionals GmbH, the parent company of GEMoaB GmbH, a clinical-stage cell therapy company.

Get Complete Analysis Of The Report - Download Free Sample PDF

CAR T-Cell Therapy Market Competitive landscape: 

The CAR T-Cell therapy market is moderately competitive with several global and international players. The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. Some of the key players in the market are 

Key Players :

• Novartis AG
• Bristol-Myers Squibb Company
• Gilead Sciences, Inc. (Kite Pharma)
• Johnson & Johnson
• Sorrento Therapeutics, Inc

Recent developments:

1) June 2022: Bristol Myers Squibb received FDA approval for Breyanzi (lisocabtagene maraleucel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, for the treatment of adult patients with large B-cell lymphoma (LBCL).

2) April 2022: Kite, a Gilead Company, received FDA approval for Yescarta (axicabtagene ciloleucel) CAR T-cell therapy for adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy.

Frequently Asked Questions (FAQ) :

Q1. What is the current CAR T-Cell Therapy Market size?

Q2. What is the Growth Rate of the CAR T-Cell Therapy Market?

Q3. Which is the leading Component Segment in the CAR T-Cell Therapy Market?

Q4. What are the factors on which the CAR T-Cell Therapy Market research is based on?